Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

This Phase 2, placebo controlled, crossover trial evaluates the effect of nebulized ensifentrine (PDE3/4 inhibitor) (3 mg, twice daily) on sputum inflammatory biomarkers in patients with COPD. Each participant receives both active drug and placebo in separate 8 week treatment periods, separated by a washout period.

Primary End-Points:
  • Percent change from baseline in sputum Acetylated Proline-Glycine-Proline (AcPGP) at Week 8.
OHTUVAYRE
Key inclusion criteria are:
  • COPD with post-bronchodilator FEV₁ 30% - 80% predicted)
  • On any long acting inhaled therapy for COPD
ClinicalTrials.gov Identifier: NCT05270525

For more detailed information on this trial please click the link above to visit ClinicalTrials.gov

Thank You

For Contacting Us!

We’ll Respond to Your Message as Soon as Possible!